摘要
目的探讨沙格列汀联合阿卡波糖对初诊老年2型糖尿病患者血糖水平的影响。方法将本院收治的66例初诊老年2型糖尿病患者按照随机均等原则分为研究组(沙格列汀+阿卡波糖)与对照组(单纯阿卡波糖),各33例。比较两组治疗效果及安全性。结果研究组治疗总有效率高于对照组(P<0.05);治疗后,两组空腹血糖、糖化血红蛋白、餐后2 h血糖、FINS水平低于就诊时,HOMA-β水平高于就诊时,且研究组优于对照组,差异有统计学意义(P<0.05);研究组低血糖发生率低于对照组,差异有统计学意义(P<0.05)。结论初诊老年2型糖尿病患者采用沙格列汀联合阿卡波糖治疗的效果更为理想,值得推广应用。
Objective To explore the effect of saxagliptin combined with acarbose on blood glucose level in elderly patients with newly diagnosed type 2 diabetes mellitus. Methods Sixty-six elderly patients newly diagnosed as type 2 diabetes in our hospital were divided into study group （saxagliptin＋acarbose） and control group （simple acarbose） in accordance with the principle of randomization, with 33 cases in each group. The efficacy and safety of the two groups were compared. Results The total effective rate in the study group was higher than that in the control group （P〈0.05）. After treatment, the levels of fasting blood glucose, glycosylated hemoglobin, 2 h postprandial blood glucose and FINS in the two groups were lower than those at the time of treatment, and the levels of HOMA-β were higher than those at the time of treatment, those of the study group were better than the control group （P〈0.05）. The incidence of hypoglycemia in the study group was lower than that in the control group （P〈0.05）. Conclusion The saxagliptin combined with acarbose on elderly patients with newly diagnosed type 2 diabetes has more satisfactory effect, and it is worth popularizing and applying.
作者
康效茹
KANG Xiao-ru(Pharmacy Department,Hancheng People＇s Hospital,Weinan 715400,China)
出处
《临床医学研究与实践》
2018年第15期18-19,共2页
Clinical Research and Practice
关键词
初诊
老年2型糖尿病
沙格列汀
阿卡波糖
血糖
newly diagnosed
elderly patients with type 2 diabetes
saxagliptin
acarbose
blood glucose
